-

Shareholder Alert: Robbins LLP Announces It Is Investigating Hallmark Financial Services Inc. (HALL) for Misleading Shareholders

SAN DIEGO & DALLAS--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating Hallmark Financial Services Inc. (NASDAQ: HALL) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Hallmark Financial underwrites, markets, distributes, and services property/casualty insurance products.

If you suffered a loss as a result of Hallmark Financial's misconduct, click here.

Hallmark Financial Services Inc. (HALL) Dismisses Its Independent Auditor

On March 2, 2020, Hallmark Financial announced that it had exited from the Binding Primary Commercial Auto Business and revealed a $63.8 million loss development for prior underwriting years. Then, on March 11, 2020, the Company disclosed it had dismissed its independent auditor BDO due in large part to a disagreement regarding estimates for reserves on unpaid losses. Finally, on March 17, 2020, Hallmark Financial filed with the SEC a letter from BDO stating BDO had expanded the scope of its audit relating to the disagreement and that "a substantial portion of the requests had not been received and/or tested prior to our termination." Following these disclosures, shares of Hallmark Financial fell from a closing price of $14.33 per share on March 2, 2020 to a closing price of $3.12 per share on March 18, 2020, representing a 78% decline.

If you purchased Hallmark Financial Services Inc. (HALL) securities between March 5, 2019 and March 17, 2020, you have until July 6, 2020, to ask the court to be appointed lead plaintiff for the class.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Hallmark Financial settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:HALL

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Notice: Robbins LLP Informs Investors of the Super Micro Computer, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Super Micro Computer, Inc. (NASDAQ: SMCI) securities between April 30, 2024 and March 19, 2026. Super Micro is a technology company that designs, develops, and manufactures high-performance server and storage systems, primarily for artificial intelligence (“AI”), data center, and cloud solutions customers. For more information, submit a form,...

BlackRock TCP Capital Corp. Investor Alert - TCPC Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired BlackRock TCP Capital Corp. (NASDAQ: TCPC) securities between November 6, 2024 and January 23, 2026. BlackRock TCP is a business development company that raises funds from investors and then uses those funds to make loans to small and midsize businesses as an alternative to bank financing. For more information, submit a form, email attorney Aa...

MREO Investor Alert - Mereo BioPharma Group plc Investors with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Mereo BioPharma Group plc. (NASDAQ: MREO) American Depository Shares ("ADS") between June 5, 2023 and December 26, 2025. Mereo is a biopharmaceutical company focused on the development of therapeutics for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the alleg...
Back to Newsroom